Shares of Merck MRK rose nearly 6% on Friday after the company announced that the EMA’s Committee for Medicinal Products for ...

Merck received a positive opinion from the European Medicines Agency backing approval of its Keytruda-Padcev combination for a subset of bladder patients.

The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international marketsReports first quarter GAAP net loss of $(1.3) billion and GAAP EPS of $(3.40), including $0.9 ...

We recently compiled a list of the 10 Most Undervalued Dow Stocks to Buy Now. Merck & Co., Inc. is among the most undervalued stocks. On April 20, MRK announced that the U.S. Food and Drug ...

A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed (cystectomy), a new study shows. The findings apply to serious cases after ...

A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed (cystectomy), a new study shows. The findings apply to serious cases after ...

Share on Pinterest A new urine test may enable more personalized treatment for bladder cancer. Image credit: SolStock/Getty Images A new urine-based test can detect minimal residual bladder cancer ...

Pfizer (PFE) and Astellas (ALPMF) (ALPMY) announced Monday that the FDA has granted priority review for their marketing application, which seeks U.S. approval for their antibody drug conjugate, Padcev ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) granted priority review for two supplemental Biologics License ...